BMO Capital Markets Increases Intercept Pharmaceuticals Price Target to $375.00 (ICPT)
Equities researchers at BMO Capital Markets raised their target price on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from $270.00 to $375.00 in a research report issued on Thursday, American Banking & Market News reports. BMO Capital Markets’ price objective points to a potential downside of 15.89% from the company’s current price.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 445.83 on Thursday. Intercept Pharmaceuticals has a one year low of $30.38 and a one year high of $497.00. The stock has a 50-day moving average of $78.93 and a 200-day moving average of $58.26. The company’s market cap is $8.620 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Thursday, November 14th. The company reported ($1.65) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.51) by $1.14. During the same quarter in the previous year, the company posted ($1.86) earnings per share. On average, analysts predict that Intercept Pharmaceuticals will post $-3.56 earnings per share for the current fiscal year.
In other Intercept Pharmaceuticals news, CMO David Shapiro sold 4,928 shares of the stock on the open market in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $71.85, for a total value of $354,076.80. The transaction was disclosed in a filing with the SEC, which is available at this link.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.